Anti-inflammatory drugs are commonly used to treat inflammation and autoimmune diseases, they help manage chronic pain, inflammation, and swelling.
The growth factor GM-CSF (Granulocyte-macrophage colony stimulating factor) has shown to be a key player in inflammation and autoimmunity. The inhibition of GM-CSF is an attractive approach for the treatment of these diseases and has proven to have a much broader range of biological activities in both innate and adaptive immune responses.
As elevated GM-CSF levels can be seen in synovial fluid and blood from patients with inflammatory disorders. Assay Ready Cells targeting GM-CSF have been developed by Euro Diagnostica (Biomonitor) and are expected to be a useful tool in the drug development process for treatment of inflammatory and autoimmune diseases.
The iLite™ GM-CSF Assay Ready Cells express luciferase under the control of a GM-CSF responsive promoter. When stimulating the cells with GM-CSF the resulting luminescent signal is proportional to the functional activity of GM-CSF in the sample. The cells can therefore be utilized as a highly sensitive assay for quantification of GM-CSF functional activity, GM-CSF inhibitor activity or neutralizing antibodies against GM-CSF in test samples, including human serum.